TrialClinical and translational science2021

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.

Ehsanollah Esfandiari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.